Clinical efficacy of tirofiban versus ateplase in patients with minor stroke
Hu Shengjie
Fu Shengqi
Zhu Lili
Li Haoran
Yu Meng
Zhang Sisen
Abstract：Objective To investigate the clinical efficacy and safety of tirofiban and rt-PA alteplase in the treatment of minor stroke patients.Methods A total of 171 patients with minor stroke ad-mitted to Department of Neurology of Zhengzhou People's Hospital from January 2021 to January 2024 were prospectively and continuously enrolled,and were randomly divided into tirofiban group(84 cases)and rt-PA group(87 cases).The tirofiban group received intravenous infusion of tirofiban but not intravenous thrombolysis therapy.The rt-PA group was treated with intravenous thrombolysis.The 90-day mRS score was observed in all patients.NIHSS was used to score the improvement of neurological function.3-month all-cause death was observed during follow-up.Results The tirofiban group had a significant larger proportion of mRS score of 0-1 at 90 d(92.86％vs 82.76％,P＜0.05),lower NIHSS scores at 24 h and 7 d after treatment and smaller proportion of early neurological deterioration than the rt-PA group(P＜0.05).Larger proportion of mRS score of 0-2 in the 90 day and slightly smaller proportion of the score of 4-6 at 90 d were observed in the tirofiban group than the rt-PA group(P＞0.05).There were no statistical difference in the incidence of 3-month all-cause death between the two groups(P＞0.05).Conclusion Compared with rt-PA,tirofiban can significantly improve the clinical prognosis of pa-tients with minor stroke,reduce the risk of early neurological deterioration,and has higher safety.
Keywords：stroketissue plasminogen activatortirofibanprognosis
Publication Date：2024-10-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1178-1181 )